Advanced Oncotherapy the end goal is very much in sight (Analyst Interview)

Advanced Oncotherapy plc (LON:AVO) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joins DirectorsTalk. Martin explains what’s been happening with the company lately, the potential advantages of LIGHT, how close we are to the first system, how AVO is funding all the work and what investors and potential investors can look forward to over the coming months.

Advanced Oncotherapy is a specialist developer and provider of a breakthrough proton therapy system, the LIGHT system, which is the result of 25 years of work at CERN and ADAM.

Its focus is on developing and supplying technologies to maximise the destructive effect of radiation on tumours whilst minimising damage to the patient’s healthy tissues.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Advanced Oncotherapy Plc

    Advanced Oncotherapy Director buys more shares in the company

    Advanced Oncotherapy (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, has told DirectorsTalk that on Monday 8th and Tuesday 9th May 2017, Professor Chris Nutting, Non-Executive Director of the Company, purchased a total

    Advanced Oncotherapy Plc

    Advanced Oncotherapy Director invests £250k into the company

    Advanced Oncotherapy (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Nick Plowman, Non-Executive Director, will invest GBP250,000 in the Company. The investment will be satisfied through the issue of 833,333

    Advanced Oncotherapy Plc

    IMRT vs Proton Therapy in Esophageal Cancer

    The current standard for treating patients with esophageal cancer is 3D radiation, but newer technologies such as intensity-modulated radiation therapy (IMRT) and proton therapy have shown the ability to reduce toxicity by limiting radiation to the

    Advanced Oncotherapy Plc

    Advanced Oncotherapy Director buys more shares in the company

    Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, has told DirectorsTalk that yesterday, Dr Enrico Vanni purchased 100,000 Ordinary Shares of 25 pence in the Company (“Ordinary Shares”) at a

    Advanced Oncotherapy Plc

    Islanders raise £27,000 for man with brain tumour

    A man diagnosed with a brain tumour in Jersey just one month ago, has been given the chance of undergoing specialist therapy, after islanders raised £27,000 for him. Friends of Rafal Tabor, 40, set up the

    Advanced Oncotherapy Plc

    Advanced Oncotherapy Plc Q&A with Hans von Celsing

    Following the new appointment at Advanced Oncotherapy Plc (LON:AVO) as Senior Independent Non-Executive Director, Mr Hans von Celsing talks to DirectorsTalk about his past experience, the present and his thoughts on the future of the company.

    Advanced Oncotherapy Plc

    Advanced Oncotherapy Directors purchase shares in the company

    Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announced this morning that yesterday the Directors below purchased ordinary shares of 25 pence in the Company. Director No of Ordinary Price

    Advanced Oncotherapy Plc

    AB Segulah increases stake in Advanced Oncotherapy plc

    TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer Advanced Oncotherapy or the underlying issuer plc of existing shares to which voting rights are attached: (ii) —————————– ——————— 2 Reason for the notification

    Hardman & Co

    Advanced Oncotherapy Plc Delivery of LIGHT

    Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world renowned CERN. The company is entering an exciting stage with construction work on